ASCLETIS-B (01672) announced that to demonstrate unwavering confidence in the company's long-term value and future prospects, Dr. Wu Jinzi (founder, chairman and chief executive officer of Ascletis, and controlling shareholder of the company) and Ms. He Jingdao (executive director and controlling shareholder of the company, spouse of Dr. Wu) have voluntarily committed not to dispose of (including but not limited to selling or pledging) any shares of the company directly or indirectly beneficially owned by them or entities controlled by them respectively, prior to the readout of the following three sets of clinical data: (i) topline data from the US Phase I clinical study of ASC47 in combination with semaglutide in obese subjects, expected to be obtained by the end of September 2025; (ii) topline data from the US 13-week Phase IIa clinical study of ASC30 oral tablets in obese or overweight subjects, expected to be obtained in December 2025; and (iii) topline data from the US Phase I single ascending dose study of ASC50 in healthy subjects, expected to be obtained in December 2025. As of the date of this announcement, the total number of shares subject to voluntary lock-up held by Dr. Wu and Ms. He is 576 million shares, representing approximately 58.03% of the company's existing issued share capital (excluding treasury shares).